New antiarrhythmic agents for the prevention and treatment of atrial fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 17, Issue SUPPL. 3, 2006, Pages

  Padanilam, Benzy J ^a   Prystowsky, Eric N ^a  

^a Care Group   (United States)

Author keywords

Atrial fibrillation; Atrial specific antiarrhythmics; Fish oil; New antiarrhythmic medications; Renin angiotensin system

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ATORVASTATIN; AZD 7009; AZIMILIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENALAPRIL; EPLERENONE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIBOSEROD; PLACEBO; RSD 1235; SEROTONIN 4 ANTAGONIST; SOTALOL; VALSARTAN;

CLINICAL TRIAL; CONFERENCE PAPER; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FISH; FOOD INTAKE; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION;

EID: 33751195467     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2006.00634.x     Document Type: Conference Paper

References (43)

1. Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M, Tang A, Wells G: Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002;87:535-543.
2. Padanilam BJ, Prystowsky EN: Should atrial fibrillation ablation be considered first-line therapy for some patients? Should ablation be first-line therapy and for whom? the antagonist position. Circulation 2005;112:1223-1229.
3. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The cardiac arrhythmia suppression trial (CAST) investigators. N Engl J Med 1989;321:406-412.
4. Padanilam BJ, Lu T, Hoshi T, Padanilam BA, Shibata EF, Lee HC: Molecular determinants of intracellular pH modulation of human Kv1.4 N-type inactivation. Mol Pharmacol 2002;62:127-134.
5. Patel SP, Campbell DL:Transient outward potassium current, 'Ito,' phenotypes in the mammalian left ventricle: Underlying molecular, cellular and biophysical mechanisms. J Physiol 2005;569:7-39.
6. Zareba KM: Dronederone: A new antiarrhythmic agent. Drugs of Today 2006;42:75-86.
7. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH: Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003;24:1481-1487.
8. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Appenzeller M, Gaud C, Biollaz J: Effect of dronederone on renal function in healthy subjects. Clin Pharmacol Ther 2005;77:10 (Abstract).
9. Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL: Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 2001;88:974-979.
10. Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM: AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004;109:990-996.
11. Wang Z, Fermini B, Nattel S: Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993;73:1061-1076.
12. Vos MA: Atrial-specific drugs: The way to treat atrial fibrillation? J Cardiovasc Electrophysiol 2004;15:1451-1452.
13. Goldstein RN, Khrestian C, Carlsson L, Waldo AL: AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004;15:1444-1450.
14. Beatch GN, Lin SP, Hesketh C, Johnson BD, Ezrin AM: Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug. Circulation 2003;108:IV-85.
15. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN: CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-2361.
16. Goegelein H, Brendel J, Busch AE, Bleich M: Effects of the novel atrial antiarrhythmic drug AVE0118 on action potentials in isolated atria. Heart Rhythm 2004;1:S168.
17. Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA: "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004;110:1717-1724.
18. van Gelder IC, Almgren O, Walfridsson H, Kulakowski P, Ronaszeki A, Dedek V, Malm A, Crijns H: Facilitation of DC cardioversion of atrial fibrillation/flutter and reduced immediate relapse with intravenous AZD7009. Circulation 2005;S II:112(17).
19. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989;2:757-761.
20. Anonymous: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. [erratum appears in Lancet 2001 Feb 24;357(9256):642]. Lancet 1999;354:447-455.
21. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M: Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997;11:485-491.
22. Ninio DM, Murphy KJ, Howe PR, Saint DA: Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol 2005;16:1189-1194.
23. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, Lefkowitz D, Siscovick DS: Fish intake and risk of incident atrial fibrillation. Circulation 2004;110:368-373.
24. Frost L, Vestergaard P: n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005;81:50-54.
25. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M: N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 2005;45:1723-1728.
26. Harrison RA, Elton PJ: Is there a role for long-chain omega3 or oilrich fish in the treatment of atrial fibrillation? Medical Hypotheses 2005;64:59-63.
27. Kjolbye AL, Knudsen CB, Jepsen T, Larsen BD, Petersen JS: Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies. J Pharmacol Exp Ther 2003;306:1191-1199.
28. Xing D, Kjolbye AL, Nielsen MS, Petersen JS, Harlow KW, Holstein-Rathlou NH, Martins JB: ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 2003;14:510-520.
29. Haugan K, Olsen KB, Hartvig L, Petersen JS, Holstein-Rathlou NH, Hennan JK, Nielsen MS: The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol 2005;16:537-545.
30. Leftheriotis DI, Theodorakis GN, Poulis D, Flevari PG, Livanis EG, Iliodromitis EK, Papalois A, Kremastinos DT: The effects of 5-HT4 receptor blockade and stimulation, during six hours of atrial fibrillation. Europace 2005;7:560-568.
31. Pokharel S, van Geel PP, Sharma UC, Cleutjens JP, Bohnemeier H, Tian XL, Schunkert H, Crijns HJ, Paul M, Pinto YM: Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 2004;110:3129-3135.
32. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677.
33. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005;45:1832-1839.
34. Herweg B, Sichrovsky T, Polosajian L, Rozenshtein A, Steinberg JS: Hypertension and hypertensive heart disease are associated with increased ostial pulmonary vein diameter. J Cardiovasc Electrophysiol 2005;16:2-5.
35. Sakabe M, Fujiki A, Nishida K, Sugao M, Nagasawa H, Tsuneda T, Mizumaki K, Inoue H: Enalapril preserves sinus node function in a canine atrial fibrillation model induced by rapid atrial pacing. J Cardiovasc Electrophysiol 2005;16:1-6.
36. Shroff SC, Kyungmoo R, Martovitz NL, Hoit BD, Stamber BS: Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006;17:534-541.
37. 1 receptor in guinea pig atrial myocytes. Circulation 2006;113:1278-1286.
38. Chen YJ, Chen SA: Electrophysiology of pulmonary veins. J Cardiovasc Electrophysiol 2006;17:220-224.
39. Chen YJ, Chen YC, Tai CT, Yeh HI, Lin CI, Chen SA: Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 2005;1-11.
40. Madrid AH, Bueno MG, Rebollo JMG, Marin I, Pena G, Bernal E, Rodriquez A, Cano L, Cano JM, Cabeza P, Moro C: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002;106:331-336.
41. Siu CW, Lau CP, Tse HF: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-1345.
42. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-1383.
43. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S: Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110:2313-2319.